Company profile: Oxford BioTherapeutics
1.1 - Company Overview
Company description
- Provider of targeted cancer medicines and companion diagnostics for selected antibody programs, developing a broad pipeline of novel antibody therapeutics using its OGAP (Oxford Genome Anatomy Project) platform, supported by strategic partnerships with leading antibody companies including Medarex, Biosite and Amgen.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oxford BioTherapeutics
NMS Group
HQ: Italy
Website
- Description: Provider of oncology research and development, managing the integrated R&D chain from pre-clinical to clinical stages. Operates a validated oncology drug discovery platform generating a pipeline of new chemical entities (NCEs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NMS Group company profile →
ValiRx
HQ: United Kingdom
Website
- Description: Provider of oncology therapeutics and diagnostics R&D in the United Kingdom, including VAL 101 that acts to shut down the Bcl-2 gene (a proto-oncogene) and human papilloma virus diagnostic products based on the Nucleosomics platform. Offers an evaluation pipeline for cancer projects, Inaphaea BioLabs cell-based assays in oncology and women’s health, and a partnering strategy to optimize development, minimize risk, and advance early-stage programs toward clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ValiRx company profile →
C4X Discovery
HQ: United Kingdom
Website
- Description: Provider of NMR-based 3D molecular structure determination to optimize drug design and development, partnering with pharma to generate better, safer products. Offers Conformetrix 4D structural design technology, 4Sight visualizer, PatientSeek for genetic patient stratification, and programs including oral α4β7 integrin inhibitors, IL-17A inhibitors (licensed to Sanofi), and NRF2 activators (licensed to AstraZeneca).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C4X Discovery company profile →
Kleo Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule therapeutics in development, including Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs), to treat cancer, infectious diseases, and other indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kleo Pharmaceuticals company profile →
Nanobiotix
HQ: France
Website
- Description: Provider of nanomedicine therapeutics for the local treatment of cancer. Develops NanoXray, a technology using inert particles to destroy cancer cells. Products include magnetic particles and laser-activated nanoparticles for treatment and diagnostic. Offers NBTXR3, a radioenhancer that increases radiotherapy dose in tumor cells without affecting surrounding healthy tissues across solid tumors, and leads NANORAY-312, a phase 3 trial in HNSCC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanobiotix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oxford BioTherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oxford BioTherapeutics
2.2 - Growth funds investing in similar companies to Oxford BioTherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oxford BioTherapeutics
4.2 - Public trading comparable groups for Oxford BioTherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →